The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
And only later did we find that it was actually part of the PI3 kinase pathway in a regular AKT. And that clarified lots of things. And in many ways, mTORC2, you could actually even say, and we've written papers arguing this, that it's almost like upstream of mTORC1 because the PI3 kinase pathway is one of the inputs into mTORC1.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.